Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes
Diabetes Care · 01.02.2024 · 47 (2) · 267-271
DOI: 10.2337/dc23-1276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 12.12.2023. Verfasst von Candice Y Kaminski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, GA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Hyperglycemia, Kidney Failure, Chronic. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIA NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Patients with diabetes and end-stage kidney disease (ESKD) may experience “burnt-out diabetes,” defined as having an HbA1c value <6.5% without antidiabetic therapy for >6 months. We aim to assess glycemic control by continuous glucose monitoring (Dexcom G6 CGM) metrics and glycemic markers in ESKD patients on hemodialysis with burnt-out diabetes. RESEARCH DESIGN AND METHODS In this pilot prospective study, glycemic control was assessed by continuous glucose monitoring (CGM), HbA1c measures, and glycated albumin and fructosamine measurements in patients with burnt-out diabetes (n = 20) and without a history of diabetes (n = 20). RESULTS Patients with burnt-out diabetes had higher CGM-measured daily glucose levels, lower percent time in the range 70–180 mg/dL, higher percent time above range (>250 mg/dL), and longer duration of hyperglycemia >180 mg/dL (hours/day) compared with patients without diabetes (all P < 0.01). HbA1c and fructosamine levels were similar; however, patients with burnt-out diabetes had higher levels of glycated albumin than did patients without diabetes. CONCLUSIONS The use of CGM demonstrated that patients with burnt-out diabetes have significant undiagnosed hyperglycemia. CGM and glycated albumin provide better assessment of glycemic control than do values of HbA1c and fructosamine in patients with ESKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Emory University School of Medicine, Atlanta, GA.
- Division of Endocrinology, Department of Medicine, Emory University, Atlanta, GA.
- Division of Nephrology, Department of Medicine, Emory University, Atlanta, GA.
- Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
- University of Maryland Institute for Health Computing, Bethesda, MD.
- Emory University Rollins School of Public Health, Atlanta, GA.
ORCID-Profile: Rodolfo J Galindo, Zohyra Zabala, Rozalina G McCoy, Maya Fayfman, Priyathama Vellanki, Thaer Idrees, Guillermo E Umpierrez
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- NIA NIH HHS
Zitieren
APA
Kaminski, C. Y., Galindo, R. J., Navarrete, J. E., Zabala, Z., Moazzami, B., Gerges, A., McCoy, R. G., Fayfman, M., Vellanki, P., Idrees, T., Peng, L., & Umpierrez, G. E. (2024). Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes. Diabetes Care, 47(2), 267-271. https://doi.org/10.2337/dc23-1276
Vancouver
Kaminski CY, Galindo RJ, Navarrete JE, Zabala Z, Moazzami B, Gerges A, et al. Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes. Diabetes Care. 2024;47(2):267-271. doi:10.2337/dc23-1276
BibTeX
@article{Kaminski2024,
author = {Kaminski, Candice Y and Galindo, Rodolfo J and Navarrete, Jose E and Zabala, Zohyra and Moazzami, Bobak and Gerges, Amany and McCoy, Rozalina G and Fayfman, Maya and Vellanki, Priyathama and Idrees, Thaer and Peng, Limin and Umpierrez, Guillermo E},
title = {Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes},
journal = {Diabetes Care},
year = {2024},
volume = {47},
number = {2},
pages = {267--271},
doi = {10.2337/dc23-1276}
}
EUVIMED